Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa Linsäter. This is my first quarterly report since assuming the CEO role on September 1st. After joining BICO in mid-2024 as Chief Commercial Officer, I have spent a lot of time with our businesses, teams, and customers. Those conversations have reinforced where we are strongest, but also where we need greater focus and discipline. I want to thank our employees, customers, and partners for their candid input, valuable insights, and continued trust in BICO. So before we turn to the third quarter results, I would like to introduce BICO 2030, our new strategy, which we are launching today.
Ewa will then cover the quarter, and I will close with our Q4 focus before the Q&A.
Let me start with the thinking behind the BICO 2030 Strategy. This is not about changing BICO's purpose or ambition. Our vision remains the same: to enable life science labs to accelerate the discoveries that change lives. BICO 2030 is about being much clearer about where we can compete, where we can create the most value, and where we should allocate our resources. To explain that, let me first take a step back and look at how we got here. BICO 2030 is the result of a three-step process during 2026. In the spring, we carried out a comprehensive, customer-focused business review across all our businesses. Over the summer, it became the basis for updated commercial plans, and this autumn, together with our assessment of the large-scale lab automation project business, it came together in one group strategy. The review confirmed that many of BICO's strongest technologies, scientific capabilities, and customer relationships already sit within what we today define as Precision Biology. We do not need to become a different company. We already have a strong foundation to build from. It also drew on what we learned from executing our previous strategy. And one conclusion stands out. An attractive market and a competitive advantage in that market are not the same thing. We did not deliver on all the ambitions of BICO 2.0, particularly in scaling Biosero into the growth platform envisioned. We underestimated what it takes to scale a large, customized product business built on third-party hardware in a market that became more competitive, capital-intensive, and disrupted by AI. The outcome is a strategy grounded in our portfolio, customer demand and BICO's competitive edge. We are concentrating on our strongest positions. So, where are our strongest positions? In total, we serve three growing markets worth around 10 billion USD. 3D biology and biomaterials are worth 2.7 billion USD and are growing at low double digits. As research shifts from animal tests to human-relevant 3D models, cell imaging, isolation, and cell line development represent a $3.4 billion market growing at high single digits, driven by new modalities such as monoclonal antibodies, cell and gene therapies, and automation. Of the wet lab, $4.1 billion, growing at mid to high single digits. As AI moves the bottleneck from discovery and design to validation in the wet lab, and as labs automate and miniaturize, our current serviceable market within these segments is approximately 1.5 billion USD, growing at an estimated 4 to 7% annually. Behind these markets is a real problem worth solving. Of around 18,500 recognized diseases, only about 4,000 have an FDA-approved treatment, which is about 1 in 5, and drug development remains long, expensive, and complex. Around $300 billion in annual R&D. It takes 10 to 15 years to bring a drug to market and $2.7 billion per approved drug, including failures. At the same time, science is moving quickly. Advanced cell models, automation and AI are changing how researchers identify, test and validate potential new therapies. The challenge is increasingly about generating better biological data earlier and more efficiently. That is the problem Precision Biology addresses and where we believe BICO can make a meaningful difference. BICO comes into play early in discovery and preclinical, the first 3 to 5 years, and about a third of R&D spend. Only 1 in 13 candidates entering clinical trials is approved, and the costliest phases come late, with phase three alone accounting for more than a quarter of R&D spend. At the same time, AI is transforming early drug discovery, accelerating target identification and the design of new molecules. As models generate candidates faster than ever, more of them need to be tested on living material, and that work still happens in the physical lab. This makes the wet lab a critical bottleneck. An AI-designed candidate cannot progress forward toward a therapy until it has been tested and validated in living biology. With that step, much of the speed gained through AI upstream is lost. More reproducible workflows, higher-quality data, and better human-relevant models can help identify weak candidates before late-stage costs and time accumulate. Our precision biology instruments and offerings are built for exactly this work, making them enablers of AI-driven drug discovery. At its core, BICO 2030 is about focus to accelerate Precision Biology.
BICO is the precision biology company. Each of our brands brings a specific capability for handling living material precisely: the growth matrix, the conditions, the placement, and the analysis. Our lead market is cell-based applications in biotech and pharma where the need for precision is greatest. That is where we will concentrate our commercial resources, innovation and capital, building on differentiated capabilities and established customer relationships. The success of BICO 2030 will be measured by our ability to translate that focus into sustainable growth, improved profitability, and stronger cash generation. Across our businesses. We have differentiated capabilities in precision biology in three areas: handling, preparing, moving, and placing biological material with products like I.DOT and UP.SIGHT. Culture. Culturing and maintaining the conditions biology needs with BIO X and our 3D matrices and analysis. Turning observations into evidence with CELLCYTE and our Rebel and Revolve microscopes. And these are just a few examples. Automation, AI, and consumables run across all three. Importantly, we do not need to build these from scratch. These capabilities exist in our products today.
So how will BICO 2030 translate into value creation? And importantly, how should you expect to see progress over time? This strategy is built around three priorities. First, Precision Biology. At the core, we will concentrate resources on cell solutions and 3D cell models where our competitive advantage is strongest. Large-scale integrated lab automation projects will no longer be a core focus. We are assessing strategic options for Biosero to determine its best long-term path. Importantly, we are not moving away from lab automation itself, but from large, highly customized integration projects built around third-party instruments and third-party automation hardware. The value creation logic is straightforward: accelerate organic sales growth in our high-quality and, in some cases, world-leading instruments, increase the share of consumables, services, and software, and reduce our exposure to large, customized projects that have reduced profitability. Second, customer-driven innovation enabled by AI, R&D will be more closely aligned with customer demand. We will use AI in product development, make instruments ready for software agents and robots, and increasingly incorporate AI into the products themselves, complemented by selective bolt-on acquisitions. This should give us higher returns on R&D, faster development, and software revenue on our installed base. Third, accountability close to the customer. Our business units will own growth, profitability, and execution, supported by a lean group function, driving strong commercial execution and operating leverage. Together, these priorities are how we intend to achieve our financial targets. And that brings me naturally to our financial ambitions. First, three observations. Past performance showed the group has not consistently reached its financial targets. What Biosero taught us is that large-scale automation projects did not provide the leading, scalable platform we envisioned, and this is what the review confirmed. We already have businesses that drive growth and profitability. So, the strategic choice is to focus where BICO has the clearest competitive advantage and the strongest path to profitable growth. BICO 2030 changes where we focus and how we execute, but it does not change our financial ambition. The board has reconfirmed our existing long-term financial targets: double-digit organic growth in constant currencies, an EBITDA margin (less capitalized development costs) of about 10%, and a net debt to EBITDA ratio below three times. New long-term financial targets will be defined once the current targets have been achieved. We are also strengthening our executive management to increase business accountability and bring decision-making closer to our customers. As of today, Ewa and I will be joined by three new members. Julian Riba joins as Chief Technology Officer, bringing deep experience in developing and bringing life science instruments to market with a strong focus on advancing our AI capabilities across products and R&D. Petros Apostolopoulos joins as Managing Director of Lab Instruments, with a particular focus on businesses including the SCIENION, Athena, and Echo, as well as the strategic development of our broader offering. Avijit Minocha joins as Managing Director of SCIENION, bringing extensive commercial and operational experience from across the group. Together, these changes bring business leadership closer to group decision-making and strengthen the connection between customers, commercial priorities, and technology development.
At the same time, Katherine Woodland and Jesper Höglund will continue in their current roles and as members of our extended leadership team, but will leave the executive management.
Strategy ultimately comes down to execution, and execution depends on culture. For us, that culture will be built around three values. Ownership means clear accountability for our actions, decisions, and results, and following through on our commitments. Innovation means curiosity and the courage to explore new ideas, embracing technology and new ways of working to keep finding better ways forward. And impact means the difference our work makes, helping our customers succeed and contributing to discoveries and therapies that can change lives. Ownership. Innovation. Impact.
This is a culture we are building and how we will execute. BICO 2030. Today I have deliberately focused on the high-level strategic direction. On November 25th, we will host a dedicated Strategy Deep Dive, where we will go further into BICO 2030 and how we intend to execute this strategy. You can register at bico.com/investors. Today is also about our Q3 interim report. So, I will now hand over to Ewa Linsäter to take you through our third quarter financial performance.